Clinical data | |
---|---|
Trade names | many |
AHFS/Drugs.com | Monograph |
MedlinePlus | a690007 |
Pregnancy category |
|
Routes of administration |
by mouth (capsule or suspension) |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 40% to 50% |
Protein binding | Approximately 60% |
Biological half-life | Variable Average 3 to 4 hours |
Excretion | Kidney and biliary |
Identifiers | |
|
|
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
ECHA InfoCard | 100.119.331 |
Chemical and physical data | |
Formula | C16H15N5O7S2 |
Molar mass | 453.452 g/mol |
3D model (JSmol) | |
|
|
|
|
(what is this?) |
Cefixime is an antibiotic useful to treat a number of bacterial infections. This includes otitis media, strep throat, pneumonia, urinary tract infections, gonorrhea, and Lyme disease. For gonorrhea typically only one dose is required. In the United States it is a second line treatment to ceftriaxone for gonorrhea. It is taken by mouth.
Common side effects include diarrhea, abdominal pain, and nausea. Serious side effects may include allergic reactions and Clostridium difficile diarrhea. It is not recommended in people with a history of a severe penicillin allergy. It appears to be relatively safe during pregnancy. It is in the third generation cephalosporin class of medications. It works by disrupting the bacteria's cell wall resulting in its death.
Cefixime was approved for medical use in the United States in 1989. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. It is not available as a generic medication in the United States. The wholesale cost in the developing world is about 0.26 to 2.09 USD per dose. In the United States a course of treatment costs about 100 to 200 USD as of 2015.